Medtronic Clears all Anti-trust Hurdles for Covidien Acquisition
Tuesday, December 23, 2014
Source: Mass Device
Medtronic (NYSE:MDT) said today that it's received all the anti-trust clearances it needs to go ahead with its $43 billion merger with Covidien (NYSE:COV).
The proposed merger is still subject to the approval of both companies' shareholders and the Irish High Court. Medtronic said the shareholder votes are on track to be held Jan. 6, 2015, now that it's won nods from anti-trust regulators in the U.S., the European Union, China, South Korea and Canada.